KROS - Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07 August, 04 2022 05:41 PM Keros Therapeutics Inc. Keros Therapeutics press release ( NASDAQ: KROS ): Q2 GAAP EPS of -$1.13 misses by $0.07 . Cash and cash equivalents OF $215.62M For further details see: Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07